Find C-Met Inhibitors, ARQ 197 Inhibitor, Tivantinib Inhibitor on Industry Directory, Reliable Manufacturer/Supplier/Factory from China.

Inquiry Basket (0)

SGX-523 1022150-57-7

Product Description

.cp_wz table {border-top: 1px solid #ccc;border-left:1px solid #ccc; } .cp_wz table td{border-right: 1px solid #ccc; border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;} .cp_wz table th {border-right: 1px solid #ccc;border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;}


Molecular Weight:

359.41 SGX-523 is a selective Met inhibitor with IC50 of 4 nM, no activity to BRAFV599E, c-Raf, Abl and p38α. Phase 1.


Biological Activity


SGX-523 belongs to the class of c-Met/hepatocyte growth factor receptor
(HGFR) tyrosine kinase Inhibitors. SGX-523 stabilizes MET in a unique
inactive conformation that is inaccessible to Other protein kinases,
suggesting an explanation for its selectivity. SGX523 potently inhibits
the purified MET catalytic domain but not the closely related receptor
tyrosine kinase RON. SGX523 indicates ATP-competitive inhibition with
higher apparent affinity for the less active, unphosphorylated form of
MET [MET-KD(0P), with a Ki of 2.7 nM] versus the more active
phospho-enzyme [MET-KD(3P), with a Ki of 23 nM], a phenomenon consistent
with preferential binding to an inactive enzyme conformation.